SecBot SecBot
8-K ·Filed Nov 6, 2026

TMCI

TREACE MEDICAL CONCEPTS, INC.
NEUTRAL
Impact 4/10
Horizonweeks Processed11d 14h ago SEC0001193125-26-450715
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Revenue continues to decline YoY but the pace of decline is moderating and the company reached positive Adjusted EBITDA for the first time. Watch for Q4 revenue to see if the improving year-over-year growth rate materializes as headwinds annualize, and monitor cash burn trajectory given $39.8M in cash/securities against $56.3M in debt.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$4.03
T+0 close · Nov 6, 2026 · via day close
Latest settled
+30.77%
T+5 · $5.27
Vs SPY
+28.17%
α at T+5
Next horizon
T+20
in 19d
  1. T+0 · Nov 6 $4.03entry
  2. T+1 · 9d ago +18.61%α +16.24% · $4.78
  3. T+5 · 5d ago +30.77%α +28.17% · $5.27
  4. T+7 · todayOpen
  5. T+20 · in 19d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Treace Medical Concepts reported Q3 2026 revenue of $48.3M, down 4% YoY from $50.2M, but net loss narrowed 23% to $(12.6)M and Adjusted EBITDA turned positive at $0.3M. The company narrowed its full-year 2026 revenue guidance to $206M-$210M (from $204M-$212M) and improved its Adjusted EBITDA loss guidance to $1.0M-$2.0M (from $3.0M-$5.0M). Revenue decline persists due to product mix shift toward lower-priced minimally invasive products, though case volume grew double digits.

Key Financial Metrics

EPS
−$0.19
est −$0.25 · +24.0%
Revenue
$48.3M
est $47.7M · +1.2% · -3.9% YoY
Rating
beat
Guidance
$206M-$210M
maintained
Free Cash Flow
-$8.1M
Gross Margin
79.5%

Key Facts

  • Q3 2026 revenue $48.3M, down 4% from $50.2M in Q3 2025
  • GAAP net loss $(12.6)M, improved 23% from $(16.3)M in Q3 2025
  • Adjusted EBITDA turned positive to $0.3M from $(2.6)M in Q3 2025
  • Full-year 2026 revenue guidance narrowed to $206M-$210M from $204M-$212M
  • Full-year 2026 Adjusted EBITDA loss guidance improved to $1.0M-$2.0M from $3.0M-$5.0M
  • Year-to-date cash usage reduced 53% or $9.7M vs prior year
  • Cash, cash equivalents and marketable securities totaled $39.8M as of September 30, 2026
  • Approximately 45% of Lapiplasty surgeon users now use at least one of three new bunion systems launched in Q3 2025, up from 40% in Q2 2026

Financial Impact

Revenue $48.3M, net loss $(12.6)M, Adjusted EBITDA $0.3M

revenuenet lossadjusted EBITDAcash usage

Risk Factors

  • Revenue declined 4% YoY driven by mix shift to lower-priced minimally invasive products and lower bunion kit volumes
  • Cash and marketable securities declined to $39.8M from $45.6M at June 30, 2026
  • Full-year revenue guidance still implies a decline of 1% to 3% vs 2025
  • Company remains unprofitable on a GAAP basis with accumulated deficit of $295.4M

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
10% bullish (10 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-450715
Document: tmci-20261106.htm0001193125-26-450715
Document: 0001193125-26-450715-index-headers.html0001193125-26-450715
Document: 0001193125-26-450715-index.html0001193125-26-450715
Document: 0001193125-26-450715.txt0001193125-26-450715
8-K Data (Synthetic)0001193125-26-450715

Track record

11 reports on TMCI

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +12.39% at T+60 after the Jul 13, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 16, 20261d ago SC 13G Neutral 4/10 Entry $4.42 to $4.44 Now $4.44 +0.45% ▲ +0.45% +1.47% vs SPY
  2. Nov 16, 20261d ago SC 13G/A Bearish 4/10 Entry $4.42 to $4.44 Now $4.44 −0.45% ▼ −0.45% −1.47% vs SPY
  3. Nov 12, 20266d ago Court Ruling Neutral 4/10 Entry $5.27 to $4.42 Now $4.44 −15.75% ▼ −16.13% −14.22% vs SPY
  4. Nov 6, 202611d ago 8-K Neutral 4/10 Viewing Entry $4.03 to $4.78 Now $4.44 +10.17% ▲ +18.61% +16.24% vs SPY
  5. Sep 17, 20268w ago Press Release Neutral 4/10 Entry $4.49 to $4.48 Now $4.44 −1.11% ▼ −0.22% −1.77% vs SPY
  6. Aug 7, 202614w ago 8-K Mixed 6/10 Entry $4.76 to $4.67 Now $4.44 −6.72% ▼ −1.89% −1.86% vs SPY
  7. Jul 13, 202618w ago Court Ruling Bearish 5/10 Entry $4.44 to $4.40 Now $4.44 −0.00% ▲ +0.90% +1.30% vs SPY
  8. May 8, 202627w ago Press Release Bearish 7/10 Entry $2.01 to $1.94 Now $4.44 −120.90% ▲ +3.48% +3.71% vs SPY
  9. Apr 24, 202629w ago Press Release Neutral 1/10 Entry $1.98 to $1.92 Now $4.44 +124.24% ▼ −3.03% −3.19% vs SPY
  10. Apr 9, 202631w ago 8-K Mixed 6/10 Entry $1.53 to $1.81 Now $4.44 +190.20% ▲ +18.30% +18.36% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens Thu (11h 35m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 6, 2026